Tumor necrosis factor receptors 6α and 6β

Details Tumor necrosis factor receptors 6α and 6β Tumor necrosis factor receptors 6α and 6β

2011-08-23

2011-08-23

Saoud, Christine J (Department: 1647)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Rodent cell, per se

C435S069100, C435S325000, C530S350000, C536S023500

Reexamination Certificate

active

08003386

ABSTRACT:
The present invention relates to novel Tumor Necorsis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α & -6β polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6α & -6β activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

REFERENCES:
patent: 5620889 (1997-04-01), Lynch et al.
patent: 5632994 (1997-05-01), Reed et al.
patent: 5652210 (1997-07-01), Barr et al.
patent: 5663070 (1997-09-01), Barr et al.
patent: 5741667 (1998-04-01), Goeddel et al.
patent: 5830469 (1998-11-01), Lynch et al.
patent: 5874546 (1999-02-01), Nagata et al.
patent: 5885800 (1999-03-01), Emery et al.
patent: 6297367 (2001-10-01), Tribouley
patent: 0 861 850 (1998-09-01), None
patent: WO95/33051 (1995-12-01), None
patent: WO96/34095 (1996-10-01), None
patent: WO98/56892 (1998-12-01), None
patent: WO99/04001 (1999-01-01), None
patent: WO99/07738 (1999-02-01), None
patent: WO99/11791 (1999-03-01), None
patent: WO99/14330 (1999-03-01), None
patent: WO99/26977 (1999-06-01), None
patent: WO99/31128 (1999-06-01), None
patent: WO99/33980 (1999-07-01), None
patent: WO99/46376 (1999-09-01), None
patent: WO99/50413 (1999-10-01), None
patent: WO00/01817 (2000-01-01), None
Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, pp. 34-39, 2000.
Yan et al. Two-Amino Acid Molecular Switch in an Epithelial Morphogen That Regulates Binding to Two Distinct Receptors. Science, Vo. 290, Oct. 20, 2000, pp. 523-527.
EMBL Database Accession No. AA025673 Aug. 16, 1996.
Kwon et al., The J. of Biol. Chem., 272:14272-14276 (1997).
EMBL Database Accession No. W67560 (Oct. 16, 1996).
EMBL Database Accession No. M91489 (Oct. 29, 1992).
Gieser and Swaroop, Genomics 13(3):873-876 (Jul. 1992).
Hillier et al., Genome Research 6:807-828 (1996).
Pitti et al.,Nature, 396:699-703 (Dec. 17, 1998).
Rabinowich et al., “Lymphocyte Apoptosis Induced by Fas Ligand-expressing Ovarian Carcinoma Cells,” J. Clin. Invest. 101(11):2579-2588 (Jun. 1998).
Walker et al., “Tumor expression of Fas ligand (CD95L) and the consequences,” Current Opinion in Immunology 10:564-572 (1998).
Gratas, et al., “Up-Regulation of Fas (APO-1/CD95) Ligand and Down-Regulation of Fas Expression in Human Esophageal Cancer,” Cancer Research 58:2057-2062 (May 15, 1998).
Adams et al., Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence.Nature377 (6547 Suppl):3-174 (1995).
Adams et al., Genbank Accession No. AA325843 (Apr. 20, 1997).
Hillier et al., Genbank Accession No. AA025672 (Feb. 1, 1997).
Zhang et al., Modulation of T-cell responses to alloantigens by TR6/DcR3.J. Clin Invest. 107:1459-1468.
U.S. Appl. No. 09/912,293, Rosen et al.

Affiliated with

Also associated with

Rating

Tumor necrosis factor receptors 6α and 6β does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor necrosis factor receptors 6α and 6β, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor receptors 6α and 6β will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2777005